DIAGNOSTIC USE OF INDIVIDUAL MOLECULAR FORMS OF A BIOMARKER

• US 20100304413A1
• Filed: 11/14/2008
• Published: 12/02/2010
• Est. Priority Date: 11/15/2007
• Status: Abandoned Application

• Current Assignee: BioPorto Diagnostics A/S (Bioporto A/S)
• Original Assignee: BioPorto Diagnostics A/S (Bioporto A/S)
• Inventors: Uttenthal, Lars Otto, Bangert, Kristian
• Application Number:
  US12/743,027
• Publication Number:
  US 20100304413A1
• Time in Patent Office: Days
• US Class Current: 435/7.94
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: G01N 2800/347 Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

Methods are provided of diagnosing, monitoring or determining the severity of disease or injury by measuring individual molecular forms of neutrophil gelatinase-associated lipocalin (NGAL) in bodily fluids, including the diagnosis and monitoring of acute renal injury leading to acute renal failure in a human or mammalian subject by determining the concentration of the free monomer form of NGAL.

Claims

1-28. -28. (canceled)

29. A method of diagnosing, monitoring, or assessing the severity of, or immediate risk of developing, renal injury, disease, or disorder in a mammal by measuring the concentration of free neutrophil gelatinase-associated lipocalin (NGAL) monomer in a sample of bodily fluid from the mammal and comparing said concentration with a range of concentrations of at least one molecular form of said NGAL that occurs in individuals not known to be affected by said renal injury, disease, or disorder, whereby a deviation of the concentration of said NGAL monomer from the range of concentrations of said at least one molecular form of said NGAL indicates the presence of, severity of, or immediate risk of developing said renal injury, disease, or disorder.

30. The method of claim 29, comprising the steps of:

i) determining a value for the concentration of free NGAL monomer in the sample of bodily fluid from the mammal, and

ii) comparing the concentration value of said free NGAL monomer with a cutoff value determined from the range of free NGAL monomer concentrations in said individuals not known to be affected by said renal injury, disease, or disorder, wherein said individuals show no evidence of said renal injury, disease, or disorder,

wherein a determination that the concentration value of free NGAL monomer in said sample of bodily fluid from the mammal is greater than the cutoff value indicates the presence of, severity of or immediate risk of developing said renal injury, disease, or disorder in said mammal.

31. The method of claim 29, wherein said renal injury, disease, or disorder is acute renal failure.

32. The method of claim 31, wherein said method discriminates between an individual which does not have acute renal failure and is not at immediate risk of developing acute renal failure and an individual which may have acute renal failure or is at risk of developing acute renal failure, said method comprising the steps of:

i) determining a value for the concentration of free NGAL monomer in the sample of bodily fluid from the mammal, and

ii) comparing the concentration with a predetermined cutoff value,

wherein a determination that the concentration value of free NGAL monomer is below the cutoff value categorizes the mammal as not having and not being at immediate risk of developing acute renal failure and a determination that the concentration value of free NGAL monomer is above the cutoff value categorizes the mammal as having or being at risk of developing acute renal failure.

33. The method of claim 30 further comprising repeating steps i) and ii) one or more times.

34. The method of claim 32, wherein said steps i) and ii) are repeated within 24 hours.

35. The method of claim 34, wherein said steps i) and ii) are repeated within 15 minutes to 12 hours.

36. The method of claim 32, wherein said steps i) and ii) are repeated after a treatment for acute renal failure has been initiated or completed.

37. The method of claim 30, wherein the renal injury, disease, or disorder or the risk of developing acute renal failure is due to ischemia, a complication of an inflammatory, infective, or neoplastic disease, a critical illness of any cause requiring intensive care, a surgical intervention, or the administration of a nephrotoxic agent.

38. The method of claim 29, wherein the renal injury, disease, or disorder is due to external physical or chemical causes or is due to exposure to radiation.

39. The method of claim 29, wherein the bodily fluid is blood plasma, blood serum, or urine.

40. The method of claim 29, comprising measuring the concentration of free monomer NGAL using a molecule that binds specifically to free NGAL monomer and not to complexed forms of NGAL.

41. The method of claim 29, wherein said at least one molecular form of said NGAL comprises an NGAL homodimer or a higher oligomer of NGAL.

42. The method of claim 41, comprising measuring the concentration of said NGAL homodimer or the sum of NGAL homodimer plus higher oligomers of NGAL using a combination of binding molecules, wherein said binding molecules do not bind specifically to free NGAL monomer.

43. The method of claim 29, wherein the mammal is a human.

44. A kit or device for diagnosing, monitoring, or assessing the severity of, or immediate risk of developing, renal injury, disease, or disorder in a mammal comprising a solid support and said binding molecules of claim 42.

45. A method of diagnosing, monitoring, or assessing the presence or severity of disease or injury to an organ, tissue, or cell type in a mammal, said disease or injury being characterized by a certain pattern of concentrations of individual molecular forms of NGAL being present in a bodily fluid from said mammal, comprising measuring the concentrations of two or more individual molecular forms of NGAL in a sample of said bodily fluid and comparing the results with the pattern of said concentrations that occur in mammals having said disease or injury, whereby the presence of a particular pattern of concentrations in said sample of bodily fluid indicates the presence or severity of the corresponding type of disease or injury in said mammal.

46. The method of claim 45, comprising determining a ratio of the concentration between free NGAL monomer and NGAL homodimer.

47. The method of claim 45, comprising determining a ratio of the concentration between free NGAL monomer and the sum of NGAL homodimer plus higher oligomers of NGAL.

48. The method of claim 45, comprising determining a ratio of the concentration between molecular forms of NGAL that are free of matrix metalloproteinase 9 (MMP-9) and NGAL/MMP-9 complexes.

49. A method of diagnosing, monitoring, or assessing the presence or severity of systemic disease or disease or injury of an organ, tissue, or cell type in a mammal by measuring the concentration of NGAL homodimer in a sample of bodily fluid from the mammal and comparing said concentration with the range of concentrations of NGAL homodimer that occurs in individuals not known to be affected by said disease or injury, whereby a deviation of the concentration from said range indicates the presence or severity of said disease or injury.

50. The method of claim 49, comprising measuring the total concentration of NGAL homodimer and higher oligomers of NGAL.

51. A method of selecting a binding molecule that is capable of binding specifically to NGAL monomer comprising assaying the binding of one or more candidate binding molecules to a preparation of NGAL monomer and a preparation of NGAL homodimer, and selecting the candidate binding molecules that bind to said NGAL monomer but not to said NGAL homodimer.

52. The method of claim 51, wherein said binding molecule is a monoclonal antibody.

53. A method of selecting a binding molecule that is capable of binding specifically to a NGAL homodimer comprising assaying the binding of one or more candidate binding molecules to a preparation of NGAL monomer and a preparation of NGAL homodimer, and selecting the candidate binding molecules that bind to said NGAL homodimer but not to said NGAL monomer.

54. The method of claim 53, wherein said binding molecule is a monoclonal antibody.